Antithrombin Market to Exhibit 4.1% CAGR, Rising Prevalence of Antithrombin Deficiency Stokes Growth

The rise in prevalence of congenital antithrombin III deficiency and increasing risk of bleeding while performing surgeries are boosting the global Antithrombin Market. In a report, titled “Antithrombin Market: Global Market Analysis, Insights, and Forecasts, 2018 – 2016”, Fortune Business Insights identifies various factors enabling growth in the market.

According to the report, the global antithrombin market is anticipated to rise at 4.1% CAGR and reach a valuation of US$ 725.2 Mn by the end of 2026 from US$ 490.4 Mn in 2018. Increasing investments in research and development activities is a major factor propelling growth in the market.

Rise in Number of Antithrombin Deficiency to Boost Market

In 2018, the U.S. department of Health and Human services published a report stating that nearly 1 in every 2000 person around the world will suffer from antithrombin deficiency. This, coupled with increasing number of people suffering from health problems such as liver failure, severe burns, and nephrotic syndrome, is likely to drive the global antithrombin market during the forecast period.

Among applications, the therapeutics segment is anticipated to lead the global market and continue doing so during the forecast period. This, coupled with, the number of patients suffering from excessive blood loss while performing surgeries is driving the market for antithrombin. As per Fortune Business Insights, this segment accounted for 95.7% of the global market in 2018. 

On the basis of source, the goat milk segment is likely to exhibit the fastest growth during the forecast period owing to its clinical efficiency. While in terms of dosage form, the lyophilized segment is likely to dominate the market in the forthcoming years.

Clinical Significance of Engineered Antithrombin to Fuel its Demand

Antithrombin can be used for treating several medical conditions such as disseminated intravascular coagulation (DIC), hereditary antithrombin deficiency, sepsis, and extracorporeal membrane oxygenation (ECMO). The increasing prevalence of the above mentioned disorders is creating growth opportunities for the market. Engineered antithrombin has also gained clinical significance because it helps to prevent various perioperative and peripartum thromboembolic blood clots. The aforementioned factors are expected to drive the global antithrombin market in the future.

However, the high cost associated with antithrombin treatment may act as a major challenge, hindering the growth of the antithrombin market. Furthermore, the availability of cheaper substitutes pose threat to the market in particular.

Nevertheless, the increasing investment in research and development and increasing use of antithrombin combined with heparin for treatment purpose are creating lucrative growth opportunities for the market in the long run.

Asia Pacific Market Exhibits Growth at the Fastest Pace

Fortune Business Insights has identified the Asia Pacific market as the fastest growing region. In 2018, the market was valued at US$ 179.7 Mn. The increasing demand in Asia Pacific is a result of the rising prevalence of congenital antithrombin III deficiency 

On the other side, Europe also offers lucrative growth prospects to the antithrombin market. This is attributable to the rising adoption of human antithrombin-based products in countries such as France, Germany, UK, and others.

According to Fortune Business Insights, three companies namely Grifols, CSL Behring, and Shire held dominant share in the market in 2018. Other companies operating in the global antithrombin market are Scripps Laboratories Inc., Lee Biosolutions, Octapharma AG, Kedrion S.p.A., and LFB USA.

Browse Complete Report Details @ https://www.fortunebusinessinsights.com/industry-reports/antithrombin-market-100470

 SEGMENTATION